Vicarious Surgical Elects Victoria Carr-Brendel to Board

WALTHAM, Mass.–(BUSINESS WIRE)–Vicarious Surgical Inc., a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced the appointment of Victoria Carr-Brendel, Ph.D. to the Vicarious Surgical Board of Directors effective today, January 23, 2023. The Company also announced the resignation of technology-focused venture capitalist Phil Liang from the Vicarious Surgical Board of Directors effective as of today.

“On behalf of the board, I’d like to thank Phil for his critical guidance and expertise as Vicarious Surgical navigated the pathway from tech start-up to publicly traded surgical robotics company,” said David Styka, Chairman of the Vicarious Surgical Board. “We are thrilled to welcome Victoria to the Vicarious Surgical team. I’m confident that her decades of experience bringing innovative medical devices from concept to commercialization will prove to be a significant asset in contemplation of a market-ready system.”

“I’m excited to join Vicarious Surgical at such a critical stage in their development efforts,” said Dr. Carr-Brendel. “At this point in its trajectory, robotic assisted surgery possesses the potential to impact many more patients than are treated by today’s technology. With its unique value proposition, I believe Vicarious Surgical is well positioned to deliver a solution that disrupts the current market and delivers tremendous value to patients and providers.”

Dr. Carr-Brendel possesses twenty-four years of medical device development experience leading R&D, new product development, divisional, and business development functions. She currently serves as the Group Vice President of Cochlear Implants at Sonova Group/President of Advanced Bionics, a Sonova company and a global leader in the treatment of severe-to-profound hearing loss. Prior to this, Dr. Carr-Brendel served as the Chief Executive Officer for JenaValve, a private company focused on developing transcatheter aortic valve repair systems to treat patients suffering from aortic valve disease. Between 2004 and 2015, she served in roles of increasing responsibility at Boston Scientific, eventually overseeing the acquisition of Bayer’s Interventional radiology division in 2014.

Dr. Carr-Brendel received a Bachelor’s degree in Biology from Monmouth College, a Master of Science in Microbiology from Iowa State University, and a Ph.D. in Microbiology and Immunology from the University of Illinois at Chicago.

About Vicarious Surgical

Founded in 2014, Vicarious Surgical is a next generation robotics company developing a disruptive technology with the goals of increasing the efficiency of surgical procedures, improving patient outcomes, and reducing healthcare costs. The Company’s novel surgical approach uses proprietary human-like surgical robots to transport surgeons inside the patient to perform minimally invasive surgery. The Company is led by an experienced team of technologists, medical device professionals and physicians, and is backed by technology luminaries including Bill Gates, Vinod Khosla’s Khosla Ventures, Innovation Endeavors, Jerry Yang’s AME Cloud Ventures, Sun Hung Kai & Co. Ltd and Philip Liang’s E15 VC. The Company is headquartered in Waltham, Massachusetts. Learn more at